139 related articles for article (PubMed ID: 11361607)
1. DaunoXome approved.
AIDS Patient Care STDS; 1996 Aug; 10(4):263. PubMed ID: 11361607
[No Abstract] [Full Text] [Related]
2. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
3. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White RM
AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
[No Abstract] [Full Text] [Related]
4. [New data: daunoxome against Kaposi sarcoma. Fifth European Conference on clinical aspects and treatment of HIV infection].
Pharm Unserer Zeit; 1996 Jan; 25(1):42-3. PubMed ID: 8882752
[No Abstract] [Full Text] [Related]
5. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50-1. PubMed ID: 11363534
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel for treating KS.
Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
[TBL] [Abstract][Full Text] [Related]
7. Liposomal KS drugs approved.
GMHC Treat Issues; 1996 Apr; 10(4):8-9. PubMed ID: 11363710
[TBL] [Abstract][Full Text] [Related]
8. Liposomal doxorubicin.
Linsky KF; Ignoffo RJ
Cancer Pract; 1996; 4(5):288-90. PubMed ID: 9004577
[No Abstract] [Full Text] [Related]
9. DOXIL approved by FDA.
AIDS Patient Care; 1995 Dec; 9(6):306. PubMed ID: 11361446
[No Abstract] [Full Text] [Related]
10. DaunoXome data presented at international cancer meeting.
Oncology (Williston Park); 1996 Jun; 10(6):830. PubMed ID: 8823798
[No Abstract] [Full Text] [Related]
11. Liposomal drug targeting in the treatment of Kaposi's sarcoma.
Wernz JC
AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553
[No Abstract] [Full Text] [Related]
12. KS treatment inches forward.
Vazquez E
Posit Aware; 1996; 7(5):9. PubMed ID: 11363790
[TBL] [Abstract][Full Text] [Related]
13. DaunoXome offers KS treatment alternative.
AIDS Alert; 1996 Jun; 11(6):67-8. PubMed ID: 11363544
[TBL] [Abstract][Full Text] [Related]
14. FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services.
AIDS Alert; 1996 Jan; 11(1):11-2. PubMed ID: 11363227
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
Chew T; Jacobs M
Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
[TBL] [Abstract][Full Text] [Related]
16. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
[TBL] [Abstract][Full Text] [Related]
17. NeXstar Pharmaceuticals lauches DaunoXome.
J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):52. PubMed ID: 11363700
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
[TBL] [Abstract][Full Text] [Related]
19. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
Loke WC; Spittle MF; Mitchell S; Kulasegaram R
Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
